Teva Pharmaceutical Industries

Teva Pharmaceutical Industries operates as one of the world's largest generic pharmaceutical companies with operations in more than 60 countries. The company develops, manufactures, and markets generic medicines, specialty medicines, and active pharmaceutical ingredients.

The company's business model combines high-volume generic drug production with specialty pharmaceutical development. Teva generates revenue through generic drug sales, specialty medicines, and API sales to other pharmaceutical companies. The company is known for its expertise in developing complex generic formulations and biosimilar products.

Teva Pharmaceutical Industries employs approximately 37,000 people worldwide, with its headquarters in Tel Aviv, Israel, and major manufacturing and research facilities across North America, Europe, and Asia. The company continues to invest in research and development, complex generics, and specialty medicines.

Teva Pharmaceutical Industries was founded in 1901 in Jerusalem as a small wholesale drug business by Yitzhak Elstein, Salomon Kahan, and Moshe Levinson. The company initially focused on importing and distributing medicines in Palestine under Ottoman rule.

Throughout the early 20th century, Teva expanded its operations and began manufacturing its own pharmaceutical products. The company played a significant role in providing medicines during World War II and the establishment of the State of Israel.

In the 1960s and 1970s, Teva began its international expansion, focusing on developing generic versions of off-patent medicines. The company went public on the Tel Aviv Stock Exchange in 1951 and later listed on the NASDAQ in 1987.

Throughout the 1980s and 1990s, Teva grew through strategic acquisitions, including the purchase of Lemmon Company in the United States (1985) and several European generic drug manufacturers. These acquisitions established Teva as a major player in the global generic pharmaceutical market.

In the 2000s and 2010s, Teva expanded into specialty medicines and biologics, developing innovative treatments for conditions like multiple sclerosis and migraine. The company acquired major pharmaceutical companies including Ivax Corporation (2005) and Actavis Generics (2016), further expanding its global presence.